HLA class i-associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 299-306

  Bioley, Gilles ^a   Guillaume, Philippe ^c   Luescher, Immanuel ^c   Yen, Alice ^d   Dupont, Bo ^d   Bhardwaj, Nina ^f   Mears, Gregory ^g   Old, Lloyd J ^e   Valmori, Danila ^a,b   Ayyoub, Maha ^a  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d Lmmunology Program   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; HLA ANTIGEN CLASS 1; HLA B35 ANTIGEN; HLA CW3 ANTIGEN; MONTANIDE ISA 51; PEPTIDE; RECOMBINANT ESO PROTEIN; RECOMBINANT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MOLECULAR TYPING; NEOPLASM; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CANCER VACCINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-B35 ANTIGEN; HLA-C ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MEMBRANE PROTEINS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 58849165804     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1747     Document Type: Article

References (27)

1. Yewdell JW. Confronting complexity: real-world immunodominance in antiviral CD8+ Tcell responses. Immunity 2006;25:533-43.
2. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N EnglJ Med 2007;357:851 -62.
3. Tollefsen S, Arentz-Hansen H, Fleckenstein B, et al. HLA-DQ2 and -DQ8 signatures of gluten Tcell epitopes in celiac disease. J Clin Invest 2006;116:2226-36.
4. Altfeld M, Kalife ET, Qi Y, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) Tcell response against HIV-1. PLoS Med 2006;3:e403.
5. Lichterfeld M, Yu XG, Le Gall S, Altfeld M. Immuno- dominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. Trends Immunol 2005;26:166-71.
6. Lewinsohn DA, Winata E, Swarbrick GM, et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 2007;3:1240-9.
7. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 2007;25:3090-100.
8. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor- specific shared antigenic peptides recognized by humanTcells. Immunol Rev 2002;188:51 -64.
9. Machiels JP, van Baren N, Marchand M. Peptide-based cancer vaccines. Semin Oncol 2002;29:494-502.
10. lO.Valmori D, Souleimanian NE.Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007;104:8947-52.
11. Jager E, Karbach J, Gnjatic S, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients Proc Natl Acad Sci USA 2006;103:14453-8.
12. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of tar gets for cancer immunotherapy. Immunol Rev 2002; 188:22-32.
13. Valmori D, Levy F, Godefroy E, et al. Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin Immunol 2007;122:163-72.
14. Romero P, Dunbar PR.Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641 -50.
15. Benlalam H, Linard B, Guilloux Y, et al. Identification of five new HLA-B* 3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 2003;171:6283-9.
16. Gnjatic S, Nagata Y, Jager E, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A 2000;97:10917 - 22.
17. Jackson H, Dimopoulos N, Mifsud NA, et al. Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ Tcell responses to tumor antigen NY-ESO-1. J Immunol 2006;176:5908-17.
18. Sharma P, Gnjatic S, Jungbluth AA, et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 Tcell epitope in a patient with bladder cancer. Cancer Immun 2003;3:19.
19. Valmori D, Dutoit V, Lienard D, et al. Naturally occurring HLA-A2 restricted CD8+ Tcell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000;60:4499-506.
20. Ayyoub M, Taub RN, Keohan ML, et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004;4:7.
21. Geldmacher C, Currier JR, Herrmann E, et al. CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients J Virol 2007;81:2440-8.
22. Poland GA, Jacobson RM, Schaid D, Moore SB. Jacobsen SJ. The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine 1998;16:1869-71.
23. Kim CJ. Parkinson DR. Marincola F. Immunodomi- nance across HLA polymorphism: implications for cancer immunotherapy. J Immunother 1998;21:1 -16.
24. Salazar LG, Coveler AL, Swensen RE, et al Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol 2007:125:275 -80.
25. Zhang Y, Sun Z, Nicolay H, et al. Monitoring of anti- vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. J Immunol 2005; 174:2404-11.
26. Zhang SY, Jouanguy E, Sancho-Shimizu V, et al. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 2007;220:225-36.
27. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy Immunol Rev 2007;220:47-59.